Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLT NASDAQ:NXTC NASDAQ:TCRT NASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$5.80-2.0%$5.35$4.59▼$14.36$11.36M0.9137,749 shs22,512 shsNXTCNextCure$6.65+1.8%$5.40$2.69▼$19.20$17.48M1.3411,387 shs24,166 shsTCRTAlaunos Therapeutics$3.48-12.8%$2.46$1.31▼$6.20$8.80M-0.841.24 million shs382,768 shsUNCYUnicycive Therapeutics$4.44-6.1%$4.24$3.53▼$11.00$83.54M1.86476,967 shs322,877 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics-7.89%+18.85%+17.20%-4.77%-53.95%NXTCNextCure-4.67%+13.78%+28.80%+37.76%-57.15%TCRTAlaunos Therapeutics+7.84%+51.71%+73.48%-20.04%+81.36%UNCYUnicycive Therapeutics-0.84%+2.38%+7.99%-5.59%+30.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$5.80-2.0%$5.35$4.59▼$14.36$11.36M0.9137,749 shs22,512 shsNXTCNextCure$6.65+1.8%$5.40$2.69▼$19.20$17.48M1.3411,387 shs24,166 shsTCRTAlaunos Therapeutics$3.48-12.8%$2.46$1.31▼$6.20$8.80M-0.841.24 million shs382,768 shsUNCYUnicycive Therapeutics$4.44-6.1%$4.24$3.53▼$11.00$83.54M1.86476,967 shs322,877 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics-7.89%+18.85%+17.20%-4.77%-53.95%NXTCNextCure-4.67%+13.78%+28.80%+37.76%-57.15%TCRTAlaunos Therapeutics+7.84%+51.71%+73.48%-20.04%+81.36%UNCYUnicycive Therapeutics-0.84%+2.38%+7.99%-5.59%+30.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.00Hold$47.50718.97% UpsideNXTCNextCure 2.25Hold$25.50283.46% UpsideTCRTAlaunos Therapeutics 1.00SellN/AN/AUNCYUnicycive Therapeutics 2.75Moderate Buy$57.001,183.78% UpsideCurrent Analyst Ratings BreakdownLatest TCRT, NXTC, UNCY, and BOLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025BOLTBolt BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025NXTCNextCureWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025UNCYUnicycive TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025BOLTBolt BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025NXTCNextCureWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025TCRTAlaunos TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025UNCYUnicycive TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/15/2025UNCYUnicycive TherapeuticsBenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSpeculative Buy$21.008/15/2025BOLTBolt BiotherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.007/15/2025NXTCNextCurePiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$36.00 ➝ $15.00(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.69M1.45N/AN/A$29.89 per share0.19NXTCNextCureN/AN/AN/AN/A$28.06 per shareN/ATCRTAlaunos Therapeutics$10K769.08N/AN/A$1.29 per share2.70UNCYUnicycive Therapeutics$680K115.31N/AN/A$0.72 per share6.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$63.12M-$26.66N/AN/AN/AN/A-91.67%-53.19%11/11/2025 (Estimated)NXTCNextCure-$55.65M-$25.82N/AN/AN/AN/A-106.62%-85.20%11/6/2025 (Estimated)TCRTAlaunos Therapeutics-$4.68M-$2.46N/A∞N/AN/A-168.02%-121.37%11/13/2025 (Estimated)UNCYUnicycive Therapeutics-$36.73M-$4.12N/AN/AN/AN/A-243.13%-119.46%11/12/2025 (Estimated)Latest TCRT, NXTC, UNCY, and BOLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025NXTCNextCure-$4.06N/AN/AN/AN/AN/A8/14/2025Q2 2025BOLTBolt Biotherapeutics-$6.40-$4.46+$1.94-$4.46$0.82 million$1.80 million8/14/2025Q2 2025TCRTAlaunos Therapeutics-$5.3340-$0.63+$4.7040-$0.63N/AN/A8/14/2025Q2 2025UNCYUnicycive Therapeutics-$0.70-$0.52+$0.18-$0.52N/AN/A8/7/2025Q2 2025NXTCNextCure-$4.62-$11.29-$6.67-$11.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt BiotherapeuticsN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ATCRTAlaunos TherapeuticsN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.563.113.11NXTCNextCureN/A3.713.71TCRTAlaunos TherapeuticsN/A3.483.48UNCYUnicycive TherapeuticsN/A2.182.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%NXTCNextCure42.65%TCRTAlaunos Therapeutics27.72%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics6.10%NXTCNextCure17.90%TCRTAlaunos Therapeutics16.14%UNCYUnicycive Therapeutics10.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics901.92 million1.80 millionNot OptionableNXTCNextCure902.68 million2.20 millionOptionableTCRTAlaunos Therapeutics402.21 million1.85 millionNo DataUNCYUnicycive Therapeutics917.66 million15.77 millionNot OptionableTCRT, NXTC, UNCY, and BOLT HeadlinesRecent News About These CompaniesSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive5 hours ago | prnewswire.comHolzer & Holzer, LLC Reminds Investors of Upcoming Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Unicycive Therapeutics (UNCY) and KinderCare Learning Companies, Inc. (KLC)October 10 at 4:00 PM | globenewswire.comUNICYCIVE REMINDER: Bragar Eagel & Squire, P.C. Urges Investor to Contact the Firm Before the October 14th DeadlineOctober 10 at 1:57 PM | globenewswire.comUNCY LAWSUIT ALERT: Levi & Korsinsky Notifies Unicycive Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOctober 10 at 9:00 AM | prnewswire.comROSEN, REGARDED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure ...October 10 at 2:55 AM | caledonianrecord.comCInvestors in Unicycive Therapeutics, Inc. (UNCY): Protect Your Rights - Contact Levi & Korsinsky Before October 14, 2025October 10 at 2:55 AM | theglobeandmail.comROSEN, REGARDED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important October 14 Deadline in Securities Fraud Lawsuit – UNCYOctober 9 at 11:26 PM | globenewswire.comUnicycive Therapeutics' (UNCY) "Sell (D-)" Rating Reiterated at Weiss RatingsOctober 9 at 9:38 PM | marketbeat.comInvestors in Unicycive Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 14, 2025 to Discuss Your Rights – UNCYOctober 9 at 4:23 PM | globenewswire.comPortnoy Law Firm Announces Class Action on Behalf of Unicycive Therapeutics, Inc. InvestorsOctober 9 at 3:32 PM | globenewswire.comUNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitOctober 9 at 12:00 PM | globenewswire.comClass Action Filed Against Unicycive Therapeutics, Inc. (UNCY) Seeking Recovery for Investors - Contact The Gross Law FirmOctober 9 at 8:45 AM | prnewswire.comUNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud LawsuitOctober 8 at 10:45 PM | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCYOctober 8 at 4:30 PM | prnewswire.comUNCY DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive TherapeuticsOctober 8 at 10:45 AM | globenewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 14, 2025 in ...October 6, 2025 | caledonianrecord.comCROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – UNCYOctober 6, 2025 | globenewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 14, 2025 in Unicycive Therapeutics, Inc. Lawsuit – UNCYOctober 6, 2025 | globenewswire.comUNICYCIVE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the October 14th Deadline in the Unicycive Class Action LawsuitOctober 6, 2025 | globenewswire.comShareholders that lost money on Unicycive Therapeutics, Inc.(UNCY) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreOctober 6, 2025 | prnewswire.comUNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UnicyciveOctober 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTCRT, NXTC, UNCY, and BOLT Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$5.80 -0.12 (-2.03%) Closing price 03:59 PM EasternExtended Trading$5.88 +0.08 (+1.38%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.NextCure NASDAQ:NXTC$6.65 +0.12 (+1.84%) Closing price 04:00 PM EasternExtended Trading$6.50 -0.15 (-2.27%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.Alaunos Therapeutics NASDAQ:TCRT$3.48 -0.51 (-12.78%) Closing price 04:00 PM EasternExtended Trading$3.34 -0.15 (-4.17%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.Unicycive Therapeutics NASDAQ:UNCY$4.44 -0.29 (-6.13%) Closing price 04:00 PM EasternExtended Trading$4.54 +0.10 (+2.34%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
